Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line

Cancer Research

Volumn 61, Issue 1, 2001, Pages 8-13

  Tweddle, Deborah A ^a,b   Malcolm, Archie J ^c   Bown, Nick ^a   Pearson, Andrew D J ^b   Lunec, John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Departments of Child Health   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CHROMOSOME 17; CONTROLLED STUDY; CYTOTOXICITY; DNA SEQUENCE; FLUORESCENCE; GAMMA IRRADIATION; GENE MUTATION; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; MITOSIS INHIBITION; NEUROBLASTOMA; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DNA, NEOPLASM; GENES, P53; HUMANS; KARYOTYPING; MUTATION, MISSENSE; NEUROBLASTOMA; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035132847     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Neuroblastoma
2. LCME3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis
3. OPEC/OJEC for stage 4 neuroblastoma over 1 year of age
4. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis retinoic acid
5. p53, the cellular gatekeeper for growth and division
6. Tumor suppressor p53: Implications for tumor development and prognosis
7. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification
8. Mutations of the p53 gene are involved in Ewing's sarcornas but not in neuroblastomas
9. Absence of p53 gene mutations in primary neuroblastoma
10. Low frequency of the p53 gene mutations in neuroblastoma
11. No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis
12. Concomitant p53 mutation and MYCN amplification in neuroblastoma
13. Expression of p53 in neuroblastoma and neuroepithelioma-derived cell lines
14. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic location
15. Monoallelically expressed gene related to 1p36, a region frequently deleted in neuroblastoma and other human cancers
16. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 and p53 status
17. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones
18. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
19. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
20. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detectable mutations is associated with poor prognosis
21. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
22. Chromosomal and biochemical properties of human neuroblastoma lines and clones in cell culture
23. Increased N-myc expression following progressive growth of human neuroblastoma
24. 1checkpoint function is attenuated
25. 1checkpoint after DNA damage
26. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlation with the growth inhibitory potency of 123 anti-cancer agents
27. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: Hypersensitivity of p53-mutant human tumour xenografts